Hyperfine (HYPR) Hisse Özeti
Bir sağlık teknolojisi şirketi olan Hyperfine, Inc. manyetik rezonans görüntüleme (MRI) ürünlerinin üretimi, tedariki, servisi ve ticarileştirilmesi ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 1/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
HYPR Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Hyperfine, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$1.30 |
| 52 Haftanın En Yüksek Seviyesi | US$2.22 |
| 52 Haftanın En Düşük Seviyesi | US$0.76 |
| Beta | 1.4 |
| 1 Aylık Değişim | -5.80% |
| 3 Aylık Değişim | 17.12% |
| 1 Yıllık Değişim | 69.93% |
| 3 Yıllık Değişim | -38.10% |
| 5 Yıllık Değişim | -86.91% |
| Halka arzdan bu yana değişim | -87.01% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 18
HYPR: Emergency Imaging Adoption And Europe Approvals Will Support Stock Upside
Analysts have maintained their $2.00 price target on Hyperfine, making only minor adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support a stable valuation view. What's in the News for Hyperfine Hyperfine presented results from the PRIME trial at the Society for Academic Emergency Medicine 2026 Annual Meeting, reporting that bedside use of the Swoop portable MRI system in neurological emergencies was associated with a median imaging wait time of 1.28 hours compared with 7.76 hours for conventional MRI, and that portable MRI detected critical brain pathology that was later confirmed on standard MRI.
Anlatı Güncellemesi • Jun 04
HYPR: Expanded Global Access To Portable MRI Will Drive Future Upside
Analysts have lifted their price target on Hyperfine from $2.00 to $2.50, citing updated assumptions for revenue growth, profit margins, and future P/E that contribute to a slightly higher fair value estimate and discount rate. What's in the News Hyperfine reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this would represent 55% growth at the midpoint compared with 2025.Anlatı Güncellemesi • May 20
HYPR: European Regulatory Wins And New Loan Facility Will Support Upside
Analysts have raised their price target for Hyperfine from $1.60 to $2.00, reflecting updated assumptions regarding discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What's in the News Reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this implies 55% growth at the midpoint compared with 2025 (company guidance).Recent updates
Anlatı Güncellemesi • Jun 18
HYPR: Emergency Imaging Adoption And Europe Approvals Will Support Stock Upside
Analysts have maintained their $2.00 price target on Hyperfine, making only minor adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support a stable valuation view. What's in the News for Hyperfine Hyperfine presented results from the PRIME trial at the Society for Academic Emergency Medicine 2026 Annual Meeting, reporting that bedside use of the Swoop portable MRI system in neurological emergencies was associated with a median imaging wait time of 1.28 hours compared with 7.76 hours for conventional MRI, and that portable MRI detected critical brain pathology that was later confirmed on standard MRI.Anlatı Güncellemesi • Jun 04
HYPR: Expanded Global Access To Portable MRI Will Drive Future Upside
Analysts have lifted their price target on Hyperfine from $2.00 to $2.50, citing updated assumptions for revenue growth, profit margins, and future P/E that contribute to a slightly higher fair value estimate and discount rate. What's in the News Hyperfine reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this would represent 55% growth at the midpoint compared with 2025.Anlatı Güncellemesi • May 20
HYPR: European Regulatory Wins And New Loan Facility Will Support Upside
Analysts have raised their price target for Hyperfine from $1.60 to $2.00, reflecting updated assumptions regarding discount rates, revenue growth, profit margins, and future price-to-earnings (P/E) expectations. What's in the News Reaffirmed full year 2026 revenue guidance of approximately US$20 million to US$22 million, with management indicating this implies 55% growth at the midpoint compared with 2025 (company guidance).Analiz Makalesi • May 15
Hyperfine, Inc. (NASDAQ:HYPR) Analysts Are Pretty Bullish On The Stock After Recent Results
Hyperfine, Inc. ( NASDAQ:HYPR ) just released its quarterly report and things are looking bullish. Revenues were better...Anlatı Güncellemesi • Apr 30
HYPR: European Approvals And New Financing Will Support Future Upside Potential
Analysts have raised their price target on Hyperfine by $0.30, citing updated fair value assumptions of $1.60 per share that reflect adjusted expectations for revenue growth, profit margins, discount rate, and a higher future P/E multiple. What's in the News Received CE Marking and UK Conformity Assessment approval for the next generation Swoop portable MRI system and the latest Optive AI software, allowing commercialization across Europe and the UK.
Anlatı Güncellemesi • Apr 16
HYPR: European Approvals And Clinical Evidence Will Drive Future Upside
Analysts now set a $2.05 price target for Hyperfine, unchanged from before, reflecting updated views on discount rate, profit margin, and expected future P/E, without a shift in the overall valuation level. What's in the News Hyperfine received CE Marking and UKCA approval for its next generation Swoop system and latest Optive AI software, clearing the way for commercialization of its portable MRI technology across Europe and the UK and broadening its international reach in brain imaging (Product related announcement).Anlatı Güncellemesi • Apr 01
HYPR: Growing Clinical Evidence In Stroke And Outpatient Care Will Drive Upside
Analysts have lifted their Hyperfine price target from $1.65 to $2.05, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that adjust the stock's risk and earnings outlook in their models. What’s in the News Entered a new loan and security agreement with Horizon Technology Finance Corporation for a senior secured term loan facility of up to US$40 million, including an initial US$15 million draw and the option to access an additional US$25 million through December 31, 2027, with interest only payments through March 18, 2031 (Key Developments).Anlatı Güncellemesi • Mar 18
HYPR: Expanding Stroke And Outpatient Evidence Will Support Future Upside
Analysts have maintained their $1.65 price target for Hyperfine, citing largely unchanged assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E as the basis for this view. What's in the News The largest data set to date for stroke detection with the Swoop system reported strong evidence supporting AI powered portable MRI for ischemic stroke detection in emergency and other clinical settings.Anlatı Güncellemesi • Mar 04
HYPR: Expanding Clinical Evidence And New Trials Will Support Future Upside
Analysts have kept their price target for Hyperfine steady at $1.65, with small tweaks to assumptions such as a slightly higher discount rate, modestly better projected profit margin, and a somewhat lower future P/E helping to support the unchanged view. What's in the News The largest stroke detection data set to date for the Swoop system was reported.Anlatı Güncellemesi • Feb 18
HYPR: India Approval And Clinical Data Will Support Future Upside Potential
Analysts have modestly revised their price target for Hyperfine to $1.30, reflecting updated assumptions around a slightly lower discount rate, marginally higher revenue growth and profit margin expectations, and a small adjustment to the projected future P/E multiple. What's in the News The largest stroke detection data set for the Swoop system was published in Stroke: Vascular and Interventional Neurology.Anlatı Güncellemesi • Feb 04
HYPR: Growing Clinical Evidence And New Approvals Will Support Upside
Analysts have kept their price target for Hyperfine unchanged at $1.65, reflecting only minor adjustments to underlying model inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The largest-to-date stroke detection study with the Swoop system reported strong sensitivity and specificity for ischemic lesion detection, including very small strokes, with shorter scan times and improved brain image quality in emergency settings (Stroke: Vascular and Interventional Neurology).Anlatı Güncellemesi • Jan 21
HYPR: Expanded Clinical Use And New Regulatory Wins Will Drive Upside
Analysts have modestly adjusted their price target for Hyperfine to US$1.65, reflecting tweaks to key inputs such as a slightly lower discount rate, marginally softer revenue growth and profit margin assumptions, and a higher future P/E expectation. What's in the News Hyperfine enrolled the first patient in the Contrast PMR study, a prospective multi center trial evaluating contrast enhanced ultra low field portable MRI to support a potential future FDA submission to expand Swoop system use with gadolinium based contrast agents.Analiz Makalesi • Jan 15
Revenues Tell The Story For Hyperfine, Inc. (NASDAQ:HYPR) As Its Stock Soars 34%
Hyperfine, Inc. ( NASDAQ:HYPR ) shareholders are no doubt pleased to see that the share price has bounced 34% in the...Anlatı Güncellemesi • Jan 06
HYPR: India Approval Will Support Future Upside Potential
Analysts have modestly adjusted their price target on Hyperfine, reflecting small tweaks to the discount rate, revenue growth and future P/E assumptions while keeping fair value steady at US$1.30. What's in the News Hyperfine received regulatory approval in India for its Swoop portable MRI system from the Central Drugs Standard Control Organization, allowing commercialization across the country through a distribution partnership with Radiosurgery Global Ltd.Anlatı Güncellemesi • Dec 18
HYPR: India Approval And New MRI Software Will Drive Strong Upside Potential
Analysts have raised their price target on Hyperfine from approximately $0.85 to $1.30 per share, citing stronger projected revenue growth, slightly improved profit margins, and a higher expected future P E multiple, despite a modest uptick in the assumed discount rate. What's in the News Hyperfine received regulatory approval from India's Central Drugs Standard Control Organization to commercialize its Swoop portable MRI system nationally, opening access to advanced brain imaging in a large, under-served market (Key Developments).Anlatı Güncellemesi • Dec 04
HYPR: Expanded Clinical Use And Subscription Platform Will Drive Future Upside
Analysts have maintained their price target for Hyperfine at 1.65 dollars, reflecting largely unchanged views on the company. Slight improvements in discount rate and profit margin estimates are offset by a marginally lower future earnings multiple.Anlatı Güncellemesi • Nov 20
HYPR: Expanding Clinical Applications Will Drive 2025 Revenue Acceleration
Narrative Update on Hyperfine: Analyst Price Target Revision Analysts have slightly reduced their price target for Hyperfine from $1.70 to $1.65, citing updated forecasts for revenue growth and profit margins as key factors behind the adjustment. What's in the News Management expects fourth quarter 2025 revenue to be approximately $5 to $6 million, which would represent sequential and year-over-year quarterly growth of 60% and 137%, respectively.Anlatı Güncellemesi • Nov 05
HYPR: International Approvals And Expanded Use Will Drive Upside Momentum
Narrative Update on Hyperfine Analyst Price Target Analysts have maintained their fair value estimate for Hyperfine at $1.70. They cite largely unchanged growth projections along with only small adjustments in profit margin and discount rate assumptions.Anlatı Güncellemesi • Oct 21
Analysts Lift Hyperfine Price Target Amid Positive Studies and Stronger Revenue Growth Forecast
Analysts have raised their price target for Hyperfine from $1.42 to $1.70. They cite higher projected revenue growth and a slightly lower discount rate as reasons for a more bullish outlook.Analiz Makalesi • Oct 07
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 30% Price Jump
Despite an already strong run, Hyperfine, Inc. ( NASDAQ:HYPR ) shares have been powering on, with a gain of 30% in the...Anlatı Güncellemesi • Aug 29
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
The significant upward revision in Hyperfine’s consensus analyst price target is primarily driven by a notable increase in its forecasted Future P/E, with fair value rising from $1.19 to $1.42. What's in the News Hyperfine provided 2025 earnings guidance, expecting 10%–20% revenue growth over 2024.Anlatı Güncellemesi • Aug 15
FDA Clearances And Demographics Will Create Opportunity Despite Valuation Risks
With both Net Profit Margin and Future P/E essentially unchanged, analysts have maintained their consensus price target for Hyperfine at $1.19. What's in the News Hyperfine received FDA clearance for its next-generation portable MRI system powered by Optive AI software, delivering significant improvements in image quality, speed, and usability, targeting broader adoption across diverse care settings, including hospitals, neurology offices, and remote environments.Analiz Makalesi • Jul 23
Market Participants Recognise Hyperfine, Inc.'s (NASDAQ:HYPR) Revenues Pushing Shares 46% Higher
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a really impressive month, gaining 46% after a shaky period beforehand...Analiz Makalesi • May 16
Here's Why Hyperfine (NASDAQ:HYPR) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Yeni Anlatı • Apr 09
2025 Swoop Software Releases Will Boost Healthcare Imaging Adoption
Launching AI-powered software and expanding into neurology offices will likely enhance market penetration and diversify revenue streams.Analiz Makalesi • Mar 22
What You Can Learn From Hyperfine, Inc.'s (NASDAQ:HYPR) P/S After Its 28% Share Price Crash
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have had a horrible month, losing 28% after a relatively good period beforehand...Analiz Makalesi • Feb 05
Hyperfine, Inc. (NASDAQ:HYPR) Looks Just Right With A 25% Price Jump
Hyperfine, Inc. ( NASDAQ:HYPR ) shares have continued their recent momentum with a 25% gain in the last month alone...Analiz Makalesi • Nov 15
Analysts Are Updating Their Hyperfine, Inc. (NASDAQ:HYPR) Estimates After Its Third-Quarter Results
Shareholders might have noticed that Hyperfine, Inc. ( NASDAQ:HYPR ) filed its third-quarter result this time last...Hissedar Getirileri
| HYPR | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -9.7% | 2.2% | 1.6% |
| 1Y | 69.9% | -19.0% | 18.6% |
Getiri vs. Endüstri: HYPR geçen yıl % -19 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: HYPR geçen yıl % 18.6 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| HYPR volatility | |
|---|---|
| HYPR Average Weekly Movement | 12.4% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: HYPR hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: HYPR 'nin haftalık oynaklığı ( 12% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2014 | 102 | Maria Degois-Sainz | www.hyperfinemri.com |
Bir sağlık teknolojisi şirketi olan Hyperfine, Inc. manyetik rezonans görüntüleme (MRI) ürünlerinin üretimi, tedariki, servisi ve ticarileştirilmesi ile ilgilenmektedir. Swoop Taşınabilir MR Görüntüleme Sistemi, geleneksel MR tarayıcılarından daha düşük bir manyetik alan gücünde görüntüler üretir. Şirket ayrıca destek ve teknik yardım hizmetlerinin yanı sıra bir bulut görüntü arşivleme ve iletişim sistemi olan Hyperfine Image Viewer'ı da sunmaktadır.
Hyperfine, Inc. Temel Bilgiler Özeti
| HYPR temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$129.05m |
| Kazançlar(TTM) | -US$34.78m |
| Gelir(TTM) | US$15.33m |
8.4x
P/S Oranı-3.7x
F/K OranıHYPR aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| HYPR gelir tablosu (TTM) | |
|---|---|
| Gelir | US$15.33m |
| Gelir Maliyeti | US$7.48m |
| Brüt Kâr | US$7.85m |
| Diğer Giderler | US$42.63m |
| Kazançlar | -US$34.78m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.35 |
| Brüt Marj | 51.20% |
| Net Kâr Marjı | -226.88% |
| Borç/Özkaynak Oranı | 38.2% |
HYPR uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 12:44 |
| Gün Sonu Hisse Fiyatı | 2026/07/02 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Hyperfine, Inc. 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Marie Thibault | BTIG |
| Vijay Kumar | Evercore ISI |